Shield Therapeutics (STU:1JS) Total Assets: €55.69 Mil (As of Dec. 2025)


What is Shield Therapeutics Total Assets?

Shield Therapeutics STU:1JS Total Assets is €55.69 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

Shield Therapeutics's Total Assets for the quarter that ended in Dec. 2025 was €55.69 Mil.

During the past 12 months, Shield Therapeutics's average Total Assets Growth Rate was -0.70% per year. During the past 3 years, the average Total Assets Growth Rate was 28.10% per year. During the past 5 years, the average Total Assets Growth Rate was 7.20% per year. During the past 10 years, the average Total Assets Growth Rate was 13.80% per year.

During the past 12 years, Shield Therapeutics's highest 3-Year average Total Assets Growth Rate was 293.30%. The lowest was -16.00%. And the median was 1.20%.

Total Assets is connected with ROA %. Shield Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 was -25.32%. Total Assets is also linked to Revenue through Asset Turnover. Shield Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 was 0.44.

Shield Therapeutics  (STU:1JS) Total Assets Explanation

Total Assets is connected with ROA %.

Shield Therapeutics's annualized ROA % for the quarter that ended in Dec. 2025 is

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=-13.868/( (53.84+55.694)/ 2 )
=-13.868/54.767
=-25.32 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Shield Therapeutics's Asset Turnover for the quarter that ended in Dec. 2025 is

Asset Turnover
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=24.129/( (53.84+55.694)/ 2 )
=24.129/54.767
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Shield Therapeutics Total Assets Related Terms

Shield Therapeutics Total Assets Historical Data

* Premium members only.

The historical data trend for Shield Therapeutics's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Shield Therapeutics Total Assets Chart

Shield Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 53.02 25.13 44.75 54.89 55.69

Shield Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 44.75 43.44 54.89 53.84 55.69

Shield Therapeutics Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Shield Therapeutics's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=-12.876+68.569
=55.69

Shield Therapeutics's Total Assets for the quarter that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (Q: Dec. 2025 )+Total Liabilities (Q: Dec. 2025 )
=-12.876+68.569
=55.69

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of €55.69 Mil mean?
Shield Therapeutics (STU:1JS) has a Total Assets of €55.69 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Shield Therapeutics and its competitors.
Is Shield Therapeutics' Total Assets too high?
Shield Therapeutics' current Total Assets is €55.69 Mil.
How does Shield Therapeutics' Total Assets compare to ZTS and UTHR?
Shield Therapeutics' Total Assets of €55.69 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Drug Manufacturers company?
A good Total Assets depends on the Drug Manufacturers industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Shield Therapeutics and its competitors. Shield Therapeutics's current Total Assets is €55.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shield Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Shield Therapeutics (STU:1JS) is currently considered Modestly Undervalued. The stock's GF Value™ is €0.10, compared to a current price of €0.07 — trading 32% below its estimated fair value. The current Total Assets is €55.69 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Shield Therapeutics (STU:1JS), the current Total Assets is €55.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Shield Therapeutics Business Description

Other Exchanges SHIEF:USASTX:UK1JS:Germany
Address Gateshead Quays, Northern Design Centre, Baltic Business Quarter, Newcastle, GBR, NE8 3DF
Shield Therapeutics PLC is a commercial-stage specialty pharmaceutical company that delivers ACCRUFeR/FeRACCRU (ferric maltol), a differentiated pharmaceutical product, to address the unmet need for patients suffering from iron deficiency, with or without anemia. The company has launched ACCRUFeR in the U.S. Outside of the U.S., it has licensed the rights to specialty pharmaceutical companies. FeRACCRU is commercialised in the UK, the European Union, and Canada, with marketing rights in Australia and New Zealand. The company's operating segments are: FeRACCRU, which generates the maximum revenue, and PT20. Geographically, it generates maximum revenue from the U.S., and the rest from the Netherlands, Canada, Japan, and South Korea.